<DOC>
	<DOCNO>NCT01907009</DOCNO>
	<brief_summary>The management ( castration-resistant ) prostate cancer ( CRPC ) become increasingly complex . The use peripheral anti-androgens gonadorelin analogue ( maximum androgen blockade ) common place . Following failure approach , several strategy may employ . Both corticosteroid estrogens role increasingly chemotherapy use . The demonstration enhance survival use 3 weekly docetaxel mean view many standard care fit patient . Melphalan establish alkylating drug demonstrate activity CRPC , date , myelosuppression prevent adequate dosing . We recently conduct phase I dose escalation study use melphalan whole blood stem cell re-infusion show median overall survival 22 month , high median survival rate 19 month Docetaxel Data previous phase I study prove successful administration high dos IV Melphalan combination autologous blood infusion patient Castration-resistant prostate cancer . Rapid fall circulate tumour cell see within 2 week start Melphalan , however slow platelet recovery meant long period platelet transfusion . For study intend ass efficacy intensify intravenous melphalan autologous whole blood stem cell transplantation three treatment cycle . 39 patient enrol 3 year period least 17 patient need survive progression free least 6-months study consider positive . Mel-CAP combination chemotherapy consist two chemotherapy drug : MELPHALAN LENOGRASTIM 3 cycle alternately .</brief_summary>
	<brief_title>A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION ( PBSCT ) OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER ( MEL-CAP ) .</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Men age ≥18 year 2 . Histological diagnosis prostate cancer 3 . Progressive Castrationresistant Prostate Cancer define : rise PSA ; development new site disease presence suppress testosterone ( &lt; 1.5 nmol/l ) ; testosterone &gt; 1.5 nmol/l , maximum androgen blockade failure ( MAB ) ( MAB = GnRH analogue peripheral antiandrogen flutamide 250 mg 3x/day bicalutamide 50 mg/ day cyproterone 100mg 3x/day ) 4 . ECOG performance status 02 5 . Adequate haematological reserve : Unsupported Hb &gt; 9.0 g/l Platelets &gt; 100x109/l WBC &gt; 3x109/l Neutrophils &gt; 1.5x109/l 6 . Renal sufficiency : •Creatinine &lt; 200 µmol/l 7 . Hepatic sufficiency : Bilirubin &lt; 30 µmol/l ALT &lt; 3xULN unless due liver metastasis 8 . Able give write informed consent comply protocol study procedures 1 . Patients suffer previous hypersensitivity reaction melphalan 2 . Patients know hypersensitivity lenograstim excipients 3 . History myeloid malignancy 4 . Lenograstim administer concurrently cytotoxic chemotherapy ( i.e . day ) 5 . Previous invasive carcinoma &lt; 3 year prior study entry 6 . Cardiac condition contraindicate large volume venesection ( i.e. , active angina cardiac failure ) 7 . Current treatment another investigational medicinal ( chemotherapeutic ) product participation another investigational therapeutic ( chemotherapy ) study , time treatment period 30 day precede study entry . 8 . Life expectancy &lt; 12 week 9 . Unwilling unable provide write informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>